Non-interventional study concerning efficacy and safety of the intraperitoneal therapy with Removab(R) under routine practice conditions: Ambulant Catumaxomab Therapy: ACT
Latest Information Update: 28 May 2019
At a glance
- Drugs Catumaxomab (Primary)
- Indications Malignant ascites
- Focus Therapeutic Use
- Acronyms ACT
- Sponsors Neovii Biotech
- 07 Sep 2011 New trial record